Carbylan Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private, Subsidiary
- Established
- 2005-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.carbylan.com
Hydros and Hydros-TA Joint Therapy for Pain Associated With Knee Osteoarthritis
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-12-30
- Last Posted Date
- 2016-08-25
- Lead Sponsor
- Carbylan Therapeutics, Inc.
- Target Recruit Count
- 510
- Registration Number
- NCT02022930
Hydros Joint Therapy and Hydros-TA Joint Therapy for Pain Associated With Knee Osteoarthritis (OA)
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-06-02
- Last Posted Date
- 2011-11-03
- Lead Sponsor
- Carbylan Therapeutics, Inc.
- Target Recruit Count
- 98
- Registration Number
- NCT01134406
- Locations
- 🇨🇦
London Health Sciences Centre Research, London, Ontario, Canada
ActaVisc and ActaVisc Mx Intra-articular Injection for Pain Associated With Osteoarthritis in the Knee
Not Applicable
Terminated
- Conditions
- Interventions
- First Posted Date
- 2008-04-24
- Last Posted Date
- 2009-07-14
- Lead Sponsor
- Carbylan Therapeutics, Inc.
- Target Recruit Count
- 23
- Registration Number
- NCT00665574
- Locations
- 🇱🇻
State Hospital of Traumatology and Orthopaedics, Riga, Latvia
🇱🇻Daugavpils Pilsetas Centrala Slimnica, Daugavpils, Latvia
Study to Evaluate Safety and Effectiveness of AdvaCoat Sinus Gel
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-11-06
- Last Posted Date
- 2009-04-23
- Lead Sponsor
- Carbylan Therapeutics, Inc.
- Target Recruit Count
- 29
- Registration Number
- NCT00554190
- Locations
- 🇺🇸
Alabama Nasal & Sinus Center, Birmingham, Alabama, United States
🇺🇸Northwestern University Medical Center, Department of Otolaryngology, Chicago, Illinois, United States
🇺🇸Cleveland Nasal Sinus & Sleep, Cleveland, Ohio, United States
© Copyright 2024. All Rights Reserved by MedPath